With several key approvals in recent weeks, plans to redevelop sections of the former Winchester firearms factory at New Haven’s Science Park are moving forward with a goal of new housing, retail, lab space and neighborhood access.
Developer Alex Twining, working in tandem with New York-based LMXD and Goldman Sachs Urban Investment Group, is seeking to transform the former gun factory into a live-work-play neighborhood.
Connecticut Governor Ned Lamont has made workforce development a key issue going into his second term, and his two-year, $50.5 billion budget proposal sets aside tens of millions of dollars to address it … more
Separately, BioLaunch is a training program run by Connecticut Center for Arts & Technology, aka ConnCAT. Funded by $2.5 million in state money, it will train two cohorts a year of 15 people from the Dixwell and Newhallville neighborhoods aged 18 – 26 with GEDs to work as lab techs in biotechnology and life sciences laboratories. The participants will get paid during the program, including at internships with local biopharma companies … more
New Haven biotech company Halda Therapeutics reports positive results in preclinical trials of its oral candidate for the treatment of prostate cancer.
Halda is developing a novel class of cancer therapies called RIPTAC (Regulated Induced Proximity TArgeting Chimeras) therapeutics. It works as a novel “hold and kill” mechanism for the precision treatment of cancer, according to the company.
Cara Therapeutics reports that the New England Journal of Medicine (NEJM) has published results from the KOMFORT Phase 2 clinical trial of oral difelikefalin in patients with moderate-to-severe pruritus from notalgia paresthetica.
“Notalgia paresthetica is an underrecognized neuropathic itch disorder characterized by pruritus of the upper back for which there is no approved treatment,” said Brian Kim, M.D., MTR, lead author of the paper and Vice Chair of Research for the Kimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, NY.
“In the KOMFORT Phase 2 trial, oral difelikefalin demonstrated encouraging potential to address the significant unmet need for an effective treatment option for this burdensome condition.”
|
||||||||||||||||||||||
|
||||||||||||||||||||||
|
UConn School of Medicine Assistant Professor of Immunology Zhichao Fan is leading groundbreaking research into the novel use of a leukocyte-inhibiting drug to reduce tissue damage in patients undergoing coronary catheterization … more
Bringing together experts in plant science, law, health, and pharmaceutical sciences, UConn will host a Cannabis Symposium that aims to connect research with industry … more
BioXcel Therapeutics is reporting full data from its Phase 2a trial of BXCL701, the Company’s investigational, oral innate immune activator, in combination with KEYTRUDA® (pembrolizumab) in small cell neuroendocrine (SCNC) variant metastatic castration-resistant prostate cancer (mCRPC) patients after at least one prior line of chemotherapy for locally advanced or metastatic prostate cancer.
“These data support the further study of BXCL701 plus pembrolizumab in a Phase 2b trial for the potential treatment of small cell neuroendocrine prostate cancer,” said Rahul Aggarwal, M.D., Principal Investigator, Associate Director for Clinical Sciences, Helen Diller Family Comprehensive Cancer Center, and Associate Professor of Medicine at the University of California San Francisco (UCSF) … more
Earlier BioXcel announced that it will host a Key Opinion Leader Day focused on its lead immuno-oncology program BXCL701 for the investment community on Tuesday, February 21, 2023 from 1:00 to 3:00 p.m. ET … more
The biotechnology company Abryx has announced that it will open a manufacturing and distribution operation in Stamford, CT. It will lease 7,000 square feet of space and plans to create 17 to 25 jobs.
Abyrx develops and manufactures advanced biomaterials and therapeutic devices for use during surgical procedures.
More than two dozen New Haven city officials and local public-education leaders gathered in the library of Career High School at 140 Legion Ave. to celebrate a new fund, which will be seeded with $200,000 from developer Carter Winstanley as part of a community benefits agreement related to the 101 College St. project nearby.
City Economic Development Administrator Michael Piscitelli said on Tuesday that the fund will provide up to $3,000 per year for up to two years for students from the Hill, Dwight, and downtown neighborhoods who enroll in bioscience and STEM-related programs at Gateway Community College.
The fund will also provide up to $5,000 per year for up to four years for students from those same three neighborhoods if they enroll in the Biopath program at Southern Connecticut State University (SCSU).
Enko has raised additional funding, bringing the company’s overall capital raised to date to $150 million. Enko will use the new funds to advance the company’s product pipeline of novel crop protection chemistries and provide critical solutions for large scale global food security challenges.
“Ag-bio companies like Enko are at the leading edge of applying new digital tools to drive innovation and future proof our food supply,” said Dr. Prem Pavoor, Senior Partner, Head of India & Healthcare Investments, Eight Roads Ventures. “By investing in better crop protection, we can help improve yields, reduce waste, and create more sustainable food systems for our growing population in an increasingly unstable world.”
Enko has raised additional funding, bringing the company’s overall capital raised to date to $150 million. Enko will use the new funds to advance the company’s product pipeline of novel crop protection chemistries and provide critical solutions for large scale global food security challenges.
“Ag-bio companies like Enko are at the leading edge of applying new digital tools to drive innovation and future proof our food supply,” said Dr. Prem Pavoor, Senior Partner, Head of India & Healthcare Investments, Eight Roads Ventures. “By investing in better crop protection, we can help improve yields, reduce waste, and create more sustainable food systems for our growing population in an increasingly unstable world.”